Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Mol Ther. 2003 Aug;5(4):437-47.

Technology evaluation: TNFerade, GenVec.

Author information

1
Igeneon Immunotherapy of Cancer, Brunner Strasse 69/3, A-1230 Vienna, Austria. ralf.kircheis@igeneon.com

Abstract

TNFerade is a new gene therapy drug under development by GenVec that employs a replication-deficient adenovector carrying the gene for human tumor necrosis factor (TNF)-alpha, regulated by a radiation-sensitive promoter. TNFerade is currently undergoing phase II trials for the potential treatment of cancer.

PMID:
14513689
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Support Center